Clinical Trials Browser

OTHER × Triple Negative Breast Neoplasms × Clear all

NCT04789668 2026-03-18

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

Phase 1/2 Terminated

8 enrolled 13 charts

BreastCNSDermatologicOther hematologic neoplasmThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

NCT06649331 2026-03-17

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07478705 2026-03-17

EINSTEIN-TNBC

Phase NA Not yet recruiting

Recurrence, Triple Negative Breast Neoplasms

NCT05309655 2026-03-16

CROWN

Phase NA Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05340413 2026-03-16

RADIOLA

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05742269 2026-03-13

MIMIR-mTNBC

Triple Negative Breast Neoplasms

NCT07471815 2026-03-13

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06134375 2026-03-12

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Phase 1/2 Recruiting

Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07078604 2026-03-12

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT07084571 2026-03-12

FORTITUDE

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07466303 2026-03-12

Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06229392 2026-03-11

A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms, Influenza, Human, Triple Negative Breast Neoplasms

NCT02779855 2026-03-10

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Phase 1/2 Completed

50 enrolled 12 charts

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Ductal, Triple Negative Breast Neoplasms

NCT02455791 2026-03-09

Feasibility and Identification of Breast Cancer Patients for Potential Avoidance of Surgery

Phase NA Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06604858 2026-03-09

TELESCOPE

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07457359 2026-03-09

NEOTRIO-2

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT07458113 2026-03-09

BERLIN

Phase 2 Not yet recruiting

Brain Neoplasms, Triple Negative Breast Neoplasms

NCT07458204 2026-03-09

EPPIL

Phase 2 Not yet recruiting

Recurrence, Triple Negative Breast Neoplasms

NCT04677816 2026-03-06

Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients

Phase 2 Recruiting

Vitamin D Deficiency, Triple Negative Breast Neoplasms

NCT03941730 2026-03-05

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Phase 2 Active not recruiting

8 enrolled 9 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07069595 2026-03-05

PREDICT-RD

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07136493 2026-03-05

Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer

Phase NA Suspended

Triple Negative Breast Neoplasms

NCT06709651 2026-03-04

MINA

Triple Negative Breast Neoplasms

NCT07276880 2026-03-03

P-RAD(+)TN-DCT

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06434064 2026-03-02

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT07342283 2026-03-02

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT07441512 2026-03-02

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT03808337 2026-02-27

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

Phase 2 Recruiting

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT04468061 2026-02-27

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Phase 2 Terminated

24 enrolled 16 charts

Triple Negative Breast Neoplasms

NCT06802757 2026-02-25

PRISM-TNBC

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06976944 2026-02-23

PRELUDE

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04861077 2026-02-20

Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)

Phase EARLY_PHASE1 Recruiting

Triple Negative Breast Neoplasms

NCT02993068 2026-02-19

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

Phase NA Suspended

Triple Negative Breast Neoplasms

NCT07421479 2026-02-19

PDO-Mercurial

Active not recruiting

Triple Negative Breast Neoplasms

NCT05660083 2026-02-18

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02530489 2026-02-17

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

Phase 2 Completed

37 enrolled 8 charts

Triple Negative Breast Neoplasms

NCT04683679 2026-02-17

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06291064 2026-02-17

TARMAC

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT06744465 2026-02-17

NearWave Optical Molecular Monitoring

Phase NA Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06963905 2026-02-17

SIMONE

Phase 1/2 Recruiting

Triple Negative Breast Neoplasms

NCT07217990 2026-02-17

NoCUT-BC

Phase 1/2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03301350 2026-02-13

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

Phase 2 Completed

29 enrolled 15 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06224673 2026-02-13

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07300475 2026-02-13

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Phase 1 Not yet recruiting

Triple Negative Breast Neoplasms

NCT04348747 2026-02-12

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

Phase 2 Recruiting

Brain Neoplasms, Triple Negative Breast Neoplasms

NCT05914961 2026-02-12

Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer

Triple Negative Breast Neoplasms

NCT07407517 2026-02-12

POLARIS

Phase 3 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms